Literature DB >> 1638525

Structure-activity study and design of multidrug-resistant reversal compounds by a computer automated structure evaluation methodology.

G Klopman1, S Srivastava, I Kolossvary, R F Epand, N Ahmed, R M Epand.   

Abstract

We have studied the relation between the structure and the multidrug resistance-reversal activity of a set of diverse chemicals with the MULTICASE structure-activity program. A number of key structural features were identified as being related to multidrug resistance reversal activity. Using these key features, we identified seven new compounds predicted to have substantial activity. These were obtained and tested experimentally on a CHO/CHRC5 cell line derived from the AB1 Chinese hamster ovary line in the presence of vincristine and vinblastine. Of the seven compounds tested so far, four showed substantial reversal activity, the most potent of them exhibiting activity at par with verapamil.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1638525

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Evidence for modulatory sites at the lipid-protein interface of the human multidrug transporter P-glycoprotein.

Authors:  Debjani Mandal; Karobi Moitra; Debabrata Ghosh; Di Xia; Saibal Dey
Journal:  Biochemistry       Date:  2012-03-22       Impact factor: 3.162

Review 2.  Using purified P-glycoprotein to understand multidrug resistance.

Authors:  A B Shapiro; V Ling
Journal:  J Bioenerg Biomembr       Date:  1995-02       Impact factor: 2.945

3.  Reversal of multidrug resistance by bis(phenylalkyl)amines and structurally related compounds.

Authors:  A Ramu; N Ramu
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 4.  A new type of hazardous chemical: the chemosensitizers of multixenobiotic resistance.

Authors:  B Kurelec
Journal:  Environ Health Perspect       Date:  1997-06       Impact factor: 9.031

5.  Possibility of contribution of nucleoside transport systems to pirarubicin uptake by HL60 cells but not mononuclear cells.

Authors:  K Nagasawa; N Ohnishi; T Yokoyama
Journal:  Jpn J Cancer Res       Date:  1998-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.